Table 3.
Stage | Group | Power (W) | LLCT (s) | Q (l min−1) | Conductance (ml min−1 mmHg−1) |
---|---|---|---|---|---|
Rest | HF | 54 ± 3 | 4.3 ± 0.1 | 54 ± 13 | |
Control | 55 ± 3 | 4.5 ± 0.1 | 53 ± 15 | ||
Stage 1 | HF | 21 ± 5* | 31 ± 4 | 6.3 ± 0.6 | 80 ± 18 |
Control | 49 ± 21 | 26 ± 2 | 8.4 ± 0.6 | 90 ± 16 | |
Stage 2 | HF | 39 ± 11* | 28 ± 3 | 6.7 ± 0.7* | 84 ± 14* |
Control | 103 ± 38 | 22 ± 1 | 11.3 ± 0.9 | 115 ± 31 | |
Stage 3 | HF | 69 ± 19* | 23 ± 2 | 7.6 ± 0.7* | 89 ± 14* |
Control | 164 ± 55 | 18 ± 1 | 15.1 ± 1.0 | 141 ± 26 |
Results are mean ± SD
HF, chronic heart failure group, LLCT lung-to-lung circulation time, Q cardiac output
P < 0.05, HF group less than control group